Novo has upgraded its full-year forecast thanks to the huge success of the Wegovy pill, but analysts want to see more action ...

Abbott reported positive one-year results from the VERITAS study of its Amulet 360 left atrial appendage (LAA) closure device ...

South Korea issues revised guidance on data requirements for the regulatory evaluation of biosimilar products designed to ...

The UK’s Trading Standards office found that four in 10 counterfeit cosmetics products tested positive for potentially ...

Comments on the US FDA's GenAI medical device discussion paper reflect a divide between industry calls for regulatory ...

Oncology Center of Excellence official suggests that patient-reported outcomes may need to be collected more frequently early ...

Drug pricing experts are cautiously optimistic that the rule will engage large employers in countering questionable pharmacy ...

Abbott reported at TCT 2026 that its investigational SonicForce coronary intravascular lithotripsy (IVL) system met its ...

Vertex counts down days to povetacicept decision; BioMarin lowers guidance; Jazz sees growth for Ziihera; and Madrigal’s ...

The big pharma’s goal to return to high single-digit growth after 2028 relies on the continued momentum of newer brands and positive pipeline developments.

Clinical trial sponsors and investigators could face greater regulatory transparency under proposals by the Therapeutic Goods ...

The successor to the UK’s research application portal, IRAS, is taking shape, but drug and device trial sponsors are still ...